Genfit Discontinues VS-01 in ACLF After Safety Signal

MT Newswires Live

Sep 20

Genfit (GNFT) said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.

The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.

The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2568299026"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568299026\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568299026?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-20 04:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568299026","market":"us","top_or_hot":-1,"title":"Genfit Discontinues VS-01 in ACLF After Safety Signal","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/GNFTF\">Genfit</a> (GNFT) said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.</p><p>The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.</p><p>The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genfit Discontinues VS-01 in ACLF After Safety Signal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenfit Discontinues VS-01 in ACLF After Safety Signal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-20 04:39</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/GNFTF\">Genfit</a> (GNFT) said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.</p><p>The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.</p><p>The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4085","symbol_name":"互动家庭娱乐","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568299026","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568299026","pubTimestamp":1758314356,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genfit  said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4085":"互动家庭娱乐","VS":"Versus Systems Inc.","GNFT":"Genfit S.A.","GNFTF":"Genfit","BK4139":"生物科技"},"translate_title":"Genfit在发出安全信号后在ACLF中停用VS-01","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VS":1.5,"GNFT":1,"GNFTF":1.5},"content_text":"Genfit (GNFT) said late Friday that it will discontinue its VS-01 program in Acute-on-Chronic Liver Failure after a serious adverse event in a trial and feedback from its data monitoring committee.The company plans to shift VS-01 development to Urea Cycle Disorder, highlighting its promise in treating acute hyperammonemic crises in pediatric patients, according to the report.The decision will cut costs, extend its cash runway beyond 2028, and provide flexibility to advance ACLF programs and pursue new opportunities, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}